|
Real-time Estimate
Cboe Europe
11:20:00 2026-09-22 EDT
|
5-day change | 1st Jan Change | ||
| 116.37 CHF | +0.20% |
|
+2.28% | +6.24% |
| 11:03am | Celldex shares slip as safety concerns cloud skin drug trial win | RE |
| 10:30am | European Pharma Leaders Push for National Reforms to Boost Investment | DJ |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 269B | |||||
| 1,038B | |||||
| 649B | - | ||||
| 467B | |||||
| 355B | |||||
| 260B |
- Stock Market
- Stocks
- NOVN Stock
- Charts Novartis AG
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
